Trailblazer Tepezza for thyroid
Dear Editor, Teprotumumab is a human monoclonal antibody that blocks the insulin-like growth factor-1 receptor (IGF- 1R). Approved by the Food and Drug Administration (FDA) on January 21st, 2020, under the brand name Tepezza, to be used as the treatment for Graves eye disease in adults based on its...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pakistan Medical Association
2025-01-01
|
| Series: | Journal of the Pakistan Medical Association |
| Online Access: | https://jpma.org.pk/index.php/public_html/article/view/20296 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|